Nautilus Biotechnology (NAUT) Q4 2024 earnings summary

Executive summary

• Announced delay of proteome analysis platform launch to late 2026 to reduce technical risk and maximize performance, with a phased approach including foundational partnerships, early access programs, and broadscale deployment.

• Achieved significant R&D milestones in 2024, including advancements in reagent production, assay development, and software for single molecule protein analysis, and demonstrated world-first quantitative measurement of tau proteoforms, sparking interest from potential partners in Alzheimer's research.

• Reduced headcount by 16% to align resources and extend cash runway through 2027.

• The platform leverages machine learning and proprietary reagents to achieve unprecedented sensitivity, scale, and proteome coverage, targeting >95% of the human proteome and a $55B+ market opportunity by 2027.

• Strategic collaborations established with Genentech, Amgen, MD Anderson Cancer Center, and Buck Institute to validate and expand platform applications.

Financial highlights

• Q4 2024 operating expenses were $20.0 million, flat year-over-year and up $0.9 million sequentially.

• Q4 2024 net loss was $17.6 million, compared to $17.0 million in Q4 2023.

• FY 2024 operating expenses were $81.5 million, up 7% year-over-year; net loss was $70.8 million, up 11% from FY 2023.

• Ended 2024 with $206.3 million in cash, cash equivalents, and investments, down from $264 million at end of 2023.

• Net cash used in operating activities was $59.1 million for FY 2024, compared to $51.7 million in FY 2023.

Outlook and guidance

• Platform launch expected in late 2026, with early access program starting 6–9 months prior.

• FY 2025 operating expenses anticipated to be at or below 2024 levels.

• Cash runway projected through 2027 following workforce reduction and tight financial management.

• Key 2025 milestones: tau proteoform studies, partnership signing, and data publication.

• "Land and expand" sales model targeting pharma, biotech, academic, and core lab customers, with an average selling price above $1M.